Notícias e Atividades da HighTide Therapeutics

Veja o organograma con seus 9 executivos principais

Biografias mais buscadas da HighTide Therapeutics

• Liping Liu, Chief Executive Officer and Chief Science Officer
• Leigh Macconell, Chief Development Officer
• Li Yu, Vice President

Recentes movimentos de executivos em HighTide Therapeutics

• Li Yu antes Joint Company Secretary, agora é Vice President  (Notícia publicada em 20 de dezembro de 2024).

Criar um alerta
para seguir os movimentos de executivos da HighTide Therapeutics.

HighTide Therapeutics possui 2.350 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e Johnson & Johnson Innovative Medicine DIA (Estados Unidos).

Popular M&A news in Biotecnologia

• Transcarent and Accolade have merged  (publicado em 9 de abril de 2025)..
• Kashiv BioSciences acaba de anunciar uma arrecadação de fundos de 150 milhões de dólares. (publicado em 7 de abril de 2025).
• Atsena Therapeutics acaba de anunciar uma arrecadação de fundos de 150 milhões de dólares. (publicado em 4 de abril de 2025).

Outros contatos sugeridos na indústria do Biotecnologia

• Kristina Burow - Director da Scholar Rock
• Steven Gillis - Chairman of the Board da VBI Vaccines
• Ali Behbahani - Non-Executive Director da Adaptimmune Therapeutics

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de HighTide Therapeutics

• News - HighTide Therapeutics, Inc.
• HighTide-HighTide Therapeutics to Present Analyses of Phase 2 MASH Study at AASLD’s The Liver Meeting® 2024, Demonstrating Benefits of Berberine Ursodeoxycholate (HTD1801)
• HighTide-HighTide Therapeutics to Participate in the H.C. Wainwright 8th Annual MASH Investor Conference
• HighTide-8^th Annual MASH Drug Development Summit | HighTide Therapeutics Presents Rationales for Holistic Approaches to Treating MASH and Benefits of Berberine Ursodeoxycholate (HTD1801)
• HighTide-EASD 2024 | HighTide Therapeutics Presents Oral Reports of Phase 2 Studies, Highlighting Benefits of Berberine Ursodeoxychoate (HTD1801)
• HighTide-HighTide Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
• HighTide-HighTide Therapeutics Presents Analyses of a Phase 2 T2DM Study at the ADA Scientific Sessions, Highlighting Glycemic and Cardiometabolic Benefits of Berberine Ursodeoxycholate (HTD1801)
• HighTide-HighTide Therapeutics Presents Analyses of Phase 2a MASH Study at the 2024 International Liver Congress, Reinforcing and Further Characterizing the Efficacy and Safety of Berberine Ursodeoxcyholate (HTD1801)
• HighTide-HighTide Therapeutics Invited to Present at the Abu Dhabi Global Healthcare Week Health Leaders Forum
• HighTide-HighTide Therapeutics is Invited to Present at the FII PRIORITY Asia Summit in Hong Kong: Megatrends Shaping Humanity
• View more press releases Close

Redes sociais sobre HighTide Therapeutics

• HighTide Therapeutics na Wikipedia, Google News e Yahoo Finance
• HighTide Therapeutics na LinkedIn, Twitter e YouTube